Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given a consensus rating of “Moderate Buy” by the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $24.00.

Several equities analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 22nd. Needham & Company LLC raised their price objective on Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Bank of America boosted their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, JPMorgan Chase & Co. increased their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th.

Cellebrite DI Price Performance

NASDAQ:CLBT opened at $18.41 on Tuesday. The company has a 50 day moving average price of $17.71 and a 200-day moving average price of $16.72. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30. The firm has a market cap of $4.41 billion, a price-to-earnings ratio of 59.39, a price-to-earnings-growth ratio of 3.14 and a beta of 1.29.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The firm had revenue of $126.03 million for the quarter, compared to analysts’ expectations of $122.98 million. During the same period last year, the company posted $0.14 earnings per share. The business’s quarterly revenue was up 17.9% on a year-over-year basis. On average, sell-side analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Several institutional investors have recently modified their holdings of CLBT. Y.D. More Investments Ltd boosted its holdings in shares of Cellebrite DI by 76.2% during the 2nd quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock worth $7,065,000 after purchasing an additional 191,020 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Cellebrite DI during the second quarter worth approximately $657,000. Harbor Capital Advisors Inc. boosted its stake in Cellebrite DI by 19.4% during the second quarter. Harbor Capital Advisors Inc. now owns 145,692 shares of the company’s stock worth $2,331,000 after buying an additional 23,638 shares during the last quarter. MQS Management LLC purchased a new stake in Cellebrite DI in the 2nd quarter valued at $256,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Cellebrite DI by 11.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,287,954 shares of the company’s stock worth $20,607,000 after acquiring an additional 133,651 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.